3-4-di-o-caffeoylquinic-acid and Enterovirus-Infections

3-4-di-o-caffeoylquinic-acid has been researched along with Enterovirus-Infections* in 1 studies

Other Studies

1 other study(ies) available for 3-4-di-o-caffeoylquinic-acid and Enterovirus-Infections

ArticleYear
3,4-Dicaffeoylquinic Acid from the Medicinal Plant
    Journal of virology, 2022, 04-13, Volume: 96, Issue:7

    While infections by enterovirus A71 (EV-A71) are generally self-limiting, they can occasionally lead to serious neurological complications and death. No licensed therapies against EV-A71 currently exist. Using anti-virus-induced cytopathic effect assays, 3,4-dicaffeoylquinic acid (3,4-DCQA) from Ilex kaushue extracts was found to exert significant anti-EV-A71 activity, with a broad inhibitory spectrum against different EV-A71 genotypes. Time-of-drug-addition assays revealed that 3,4-DCQA affects the initial phase (entry step) of EV-A71 infection by directly targeting viral particles and disrupting viral attachment to host cells. Using resistant virus selection experiments, we found that 3,4-DCQA targets the glutamic acid residue at position 98 (E98) and the proline residue at position 246 (P246) in the 5-fold axis located within the VP1 structural protein. Recombinant viruses harboring the two mutations were resistant to 3,4-DCQA-elicited inhibition of virus attachment and penetration into human rhabdomyosarcoma (RD) cells. Finally, we showed that 3,4-DCQA specifically inhibited the attachment of EV-A71 to the host receptor heparan sulfate (HS), but not to the scavenger receptor class B member 2 (SCARB2) and P-selectin glycoprotein ligand-1 (PSGL1). Molecular docking analysis confirmed that 3,4-DCQA targets the 5-fold axis to form a stable structure with the E98 and P246 residues through noncovalent and van der Waals interactions. The targeting of E98 and P246 by 3,4-DCQA was found to be specific; accordingly, HS binding of viruses carrying the K242A or K244A mutations in the 5-fold axis was successfully inhibited by 3,4-DCQA.The clinical utility of 3,4-DCQA in the prevention or treatment of EV-A71 infections warrants further scrutiny.

    Topics: Antiviral Agents; Cell Line, Tumor; Chlorogenic Acid; Enterovirus A, Human; Enterovirus Infections; Heparitin Sulfate; Humans; Ilex; Molecular Docking Simulation; Plant Extracts; Plants, Medicinal

2022